Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments

Core Insights - Barinthus Biotherapeutics plc reported its financial results for the year ended December 31, 2025, highlighting a strategic focus on immunology and inflammation therapies, particularly VTP-1000 for celiac disease [1][2][6]. Financial Performance - Total research and development expenses decreased to $25.6 million in 2025 from $42.2 million in 2024, primarily due to reduced activity in legacy asset clinical programs [10][23]. - General and administrative expenses rose to $40.8 million in 2025, up from $29.7 million in 2024, reflecting increased professional fees and other costs [10][23]. - The company reported a net loss of $66.5 million for 2025, compared to a net loss of $61.1 million in 2024, resulting in a loss per share of $(1.64) [14][23]. Corporate Developments - Barinthus Bio is in the process of merging with Clywedog Therapeutics, expected to complete in the second quarter of 2026, creating a company focused on metabolic and autoimmune diseases [5][7]. - The merger will result in the combined entity being renamed "Clywedog Therapeutics Holdings, Inc." and trading under the ticker symbol "CLYD" [7]. - The single ascending dose portion of the Phase 1 AVALON trial for VTP-1000 was completed, with positive results indicating good tolerance and immune response in celiac disease patients [6][10]. Upcoming Milestones - Data from the multiple ascending dose portion of the Phase 1 AVALON clinical trial for VTP-1000 is anticipated in the second half of 2026, which includes a gluten challenge following three doses of the test medication [4][5]. - The merger with Clywedog is expected to enhance the clinical pipeline and attract high-caliber institutional investors [5][7].